Larsen AK - Search Results

1

Saccharomyces cerevisiae as a model system to study the response to anticancer agents.

Matuo R, Sousa FG, Soares DG, Bonatto D, Saffi J, Escargueil AE, Larsen AK, Henriques JA. Matuo R, et al. Among authors: larsen ak. Cancer Chemother Pharmacol. 2012 Oct;70(4):491-502. doi: 10.1007/s00280-012-1937-4. Epub 2012 Aug 1. Cancer Chemother Pharmacol. 2012. PMID: 22851206 Review.

2

DNA repair pathways involved in repair of lesions induced by 5-fluorouracil and its active metabolite FdUMP.

Matuo R, Sousa FG, Escargueil AE, Soares DG, Grivicich I, Saffi J, Larsen AK, Henriques JA. Matuo R, et al. Among authors: larsen ak. Biochem Pharmacol. 2010 Jan 15;79(2):147-53. doi: 10.1016/j.bcp.2009.08.016. Epub 2009 Aug 25. Biochem Pharmacol. 2010. PMID: 19712668

3

DNA alkylation damage and autophagy induction.

Bordin DL, Lima M, Lenz G, Saffi J, Meira LB, Mésange P, Soares DG, Larsen AK, Escargueil AE, Henriques JAP. Bordin DL, et al. Among authors: larsen ak. Mutat Res. 2013 Oct-Dec;753(2):91-99. doi: 10.1016/j.mrrev.2013.07.001. Epub 2013 Jul 18. Mutat Res. 2013. PMID: 23872363 Review.

4

ATP-dependent chromatin remodeling and histone acetyltransferases in 5-FU cytotoxicity in Saccharomyces cerevisiae.

Matuo R, Sousa FG, Bonatto D, Mielniczki-Pereira AA, Saffi J, Soares DG, Escargueil AE, Larsen AK, Henriques JA. Matuo R, et al. Among authors: larsen ak. Genet Mol Res. 2013 Apr 26;12(2):1440-56. doi: 10.4238/2013.April.26.6. Genet Mol Res. 2013. PMID: 23661467 Free article.

5

5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line.

Matuo R, Sousa FG, Escargueil AE, Grivicich I, Garcia-Santos D, Chies JA, Saffi J, Larsen AK, Henriques JA. Matuo R, et al. Among authors: larsen ak. J Appl Toxicol. 2009 May;29(4):308-16. doi: 10.1002/jat.1411. J Appl Toxicol. 2009. PMID: 19115314

6

PARPs and the DNA damage response.

Sousa FG, Matuo R, Soares DG, Escargueil AE, Henriques JA, Larsen AK, Saffi J. Sousa FG, et al. Among authors: larsen ak. Carcinogenesis. 2012 Aug;33(8):1433-40. doi: 10.1093/carcin/bgs132. Epub 2012 Mar 19. Carcinogenesis. 2012. PMID: 22431722 Review.

7

Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.

Lima M, Bouzid H, Soares DG, Selle F, Morel C, Galmarini CM, Henriques JA, Larsen AK, Escargueil AE. Lima M, et al. Among authors: larsen ak. Oncotarget. 2016 May 3;7(18):25885-901. doi: 10.18632/oncotarget.8292. Oncotarget. 2016. PMID: 27029031 Free PMC article.

8

Resistance mechanisms associated with altered intracellular distribution of anticancer agents.

Larsen AK, Escargueil AE, Skladanowski A. Larsen AK, et al. Pharmacol Ther. 2000 Mar;85(3):217-29. doi: 10.1016/s0163-7258(99)00073-x. Pharmacol Ther. 2000. PMID: 10739876 Review.

9

From DNA damage to G2 arrest: the many roles of topoisomerase II.

Larsen AK, Escargueil AE, Skladanowski A. Larsen AK, et al. Prog Cell Cycle Res. 2003;5:295-300. Prog Cell Cycle Res. 2003. PMID: 14593724 Review.

10

Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.

Skladanowski A, Côme MG, Sabisz M, Escargueil AE, Larsen AK. Skladanowski A, et al. Among authors: larsen ak. Mol Pharmacol. 2005 Sep;68(3):625-34. doi: 10.1124/mol.105.013995. Epub 2005 Jun 7. Mol Pharmacol. 2005. PMID: 15942022

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

223 results

Search Page